Anti-MSLN Antibody Cancer Treatment Patent

ChangeBridge: EPO Bulletin - Pharma (A61K)

Published March 25th, 2026

Detected April 1st, 2026

Summary

European Patent Office published patent EP3699199A2 granting Green Cross Corporation and Mogam Institute for Biomedical Research exclusive rights to anti-MSLN (mesothelin) antibody compositions for cancer treatment. The patent covers antibody therapeutics targeting MSLN, a tumor-associated antigen overexpressed in several cancers including mesothelioma, pancreatic, and ovarian cancers.

View original document View source feed page

What changed

The EPO granted patent EP3699199A2 for anti-MSLN antibody pharmaceutical compositions. The patent protects antibody sequences and formulations targeting mesothelin, a surface glycoprotein expressed on tumor cells. Designated states cover 36 European jurisdictions including Germany, France, UK, Italy, Spain, and other EU/EEA members.\n\nPharmaceutical companies developing antibody therapeutics targeting mesothelin should conduct freedom-to-operate analyses to assess potential infringement risks. Healthcare providers offering experimental MSLN-targeted treatments should verify licensing status. No immediate compliance deadline or filing required; this is an informational patent publication.

Source document (simplified)

← EPO Patent Bulletin

ANTI-MSLN ANTIBODY AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING SAME

Publication EP3699199A2 Kind: A2 Mar 25, 2026

Applicants

Green Cross Corporation, Mogam Institute for Biomedical Research

Inventors

KIM, Ki Su, JEONG, Jun Hong, KIM, Dong Sik, LIM, Yang Mi, PARK, Yong Yea, LIM, Hyung Kwon, WON, Jong Wha

IPC Classifications

C07K 16/30 20060101AFI20210521BHEP A61K 39/395 20060101ALI20210521BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →